Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

NCT03802240 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

492

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Sintilimab
DRUG: IBI305
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Placebo1
DRUG: Placebo2

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.